SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on ...

Phase III trial shows majority of patients become attack-free without ongoing meds ...

The so-called "anti-aging" and "longevity" (healthy long life) market, which aims to slow down the inevitable aging process ...

Malcolm Brenner, an internationally recognized physician‑scientist renowned for his leadership in cell and gene therapy, has ...

Qure may seek approval in the UK first while in talks with the FDA about its request for a larger, sham-controlled trial of ...

An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a positive start in an early clinical trial. Researchers running a Phase I ...

A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its ...

A research team from the Universitat Autònoma de Barcelona (UAB) has shown that a one-time administration of a gene therapy ...

India, June 12 -- A single administration of targeted gene therapy produced long-lasting reductions in muscle spasticity and ...

Preview this article 1 min The company plans to take its first therapy into the clinic next year. It closed its Bay Area HQ, ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine. Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike ...

Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...